$ACTU

ACTUATE THERAPEUTICS, INC.

CIK:0001652935|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 2,066,825	$ 2,764,805	$ 4,632,069	$ 5,985,124
General and administrative	2,839,763	3,204,072	5,980,475	6,349,337
Total operating expenses	4,906,588	5,968,877	10,612,544	12,334,461
Loss from operations	(4,906,588)	(5,968,877)	(10,612,544)	(12,334,461)
Other income (expense):
Interest expense	(5,063)	(5,062)	(10,125)	(10,125)
Interest income	45,016	24,534	130,285	78,157
Total other income, net	39,953	19,472	120,160	68,032
Net loss	$ (4,866,635)	$ (5,949,405)	$ (10,492,384)	$ (12,266,429)
Weighted-average shares of common stock outstanding, basic	23,871,850	19,646,475	23,705,417	19,572,564
Weighted-average shares of common stock outstanding, diluted	23,871,850	19,646,475	23,705,417	19,572,564
Net loss per share attributable to common stockholders, basic	$ (0.20)	$ (0.30)	$ (0.44)	$ (0.63)
Net loss per share attributable to common stockholders, diluted	$ (0.20)	$ (0.30)	$ (0.44)	$ (0.63)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating Activities:
Net loss	$ (10,492,384)	$ (12,266,429)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,697,158	2,704,372
Issuance of restricted shares in exchange for services	138,500	0
Interest accrued on license payable	10,125	10,125
Changes in operating assets and liabilities:
Prepaid assets and other current assets	161,896	370,375
Other assets	0	110,548
Accounts payable	(473,399)	1,130,116
Accrued compensation	(201,563)	499,669
Other accrued expenses	(1,262,783)	(1,351,277)
Net cash used in operating activities	(9,422,450)	(8,792,501)
Financing Activities:
Proceeds from sale of shares under At-the-Market Facility, net	1,251,213	0
Payment of taxes from withholding of common stock on settlement of restricted stock units	(527,716)	0
Proceeds from issuance of shares of common stock under June 2025 Private Placement, net of issuance costs of $43,933	0	4,621,546
Proceeds from issuance of shares of common stock under the Committed Equity Facility, net of issuance costs of $343,848	0	2,163,100
Proceeds from the exercise of stock options	0	34,115
Deferred offering costs	(34,629)	(175,226)
Net cash provided by financing activities	688,868	6,643,535
Net change in cash and cash equivalents	(8,733,582)	(2,148,966)
Cash and cash equivalents, beginning of period	13,159,423	8,641,622
Cash and cash equivalents, end of period	4,425,841	6,492,656
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	800	800
Supplemental Schedule of Noncash Financing Activities:
Deferred offering costs charged against At-the-Market Facility	1,622	0
Deferred offering costs, unpaid and accrued	25,900	119,710
Deferred offering costs charged against Committed Equity Facility	$ 0	$ 14,594

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 4,425,841	$ 13,159,423
Prepaid assets and other current assets	322,100	483,996
Total current assets	4,747,941	13,643,419
Deferred offering costs and other assets	451,398	392,491
Total assets	5,199,339	14,035,910
Current liabilities:
Accounts payable	1,076,691	1,524,190
Other accrued expenses	2,304,621	3,567,404
Accrued compensation	386,741	588,304
Accrued interest, current	37,143	27,018
Total current liabilities	3,805,196	5,706,916
Long term liabilities:
License payable	404,991	404,991
Total long-term liabilities	404,991	404,991
Total liabilities	4,210,187	6,111,907
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.000001 par value, 200,000,000 shares authorized, 24,013,577 and 23,245,203 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	24	23
Additional paid-in capital	166,089,213	162,531,681
Accumulated deficit	(165,100,085)	(154,607,701)
Total stockholders’ equity	989,152	7,924,003
Total liabilities and stockholders’ equity	$ 5,199,339	$ 14,035,910